Dhansa Labs advances reach Rs 33.9641 crore in September
Key highlights
- Dhansa Labs’ long-term loans and advances rose to Rs 33.9641 crore at September 30, 2026, from Rs 5.68 crore at March 31, 2026.
- Dhansa Labs’ capital work-in-progress increased to Rs 29.8714 crore from Rs 22.0383 crore over six months.
- Dhansa Labs’ non-current investments rose to Rs 9.30 crore from Rs 0.10 crore.
- Dhansa Labs received and utilised Rs 21.6154 crore of warrant proceeds by September 30, 2026.
powered by IRIS

Dhansa Labs Limited reported standalone long-term loans and advances of Rs 33.9641 crore at September 30, 2026, up from Rs 5.68 crore at March 31, 2026. The increase accompanied a Rs 7.8331 crore rise in capital work-in-progress and a Rs 9.20 crore increase in non-current investments during the six-month period.
Know Dhansa Labs inside out
Results, valuation, peers and who's buying, in one view.
What changed in Dhansa Labs’ standalone balance sheet?
Dhansa Labs’ standalone total assets were Rs 254.7712 crore at September 30, 2026, compared with Rs 149.2066 crore at March 31, 2026. Non-current assets increased to Rs 94.4288 crore from Rs 50.2754 crore, while total current liabilities rose to Rs 124.1485 crore from Rs 30.9906 crore.
Long-term loans and advances increased by Rs 28.2841 crore over the six months, reaching Rs 33.9641 crore from Rs 5.68 crore. The filing does not disclose counterparties, repayment terms, interest terms or a maturity profile for these advances, although its warrant-utilisation statement lists advances for plant and machinery and land-related advances among the uses of funds.
Dhansa Labs’ asset expansion was concentrated in advances, projects and investments rather than completed fixed assets. Property, plant and equipment fell to Rs 19.7522 crore from Rs 20.5445 crore, intangible assets declined to Rs 0.3017 crore from Rs 0.4436 crore, and deferred-tax assets decreased to Rs 1.1494 crore from Rs 1.4630 crore.
The balance-sheet total reported under equity and liabilities was Rs 254.7710 crore at September 30, 2026, versus Rs 149.2066 crore at March 31, 2026. This differs by Rs 0.0002 crore from the total-assets figure in the statement, reflecting the figures presented in the filing.
How much did Dhansa Labs deploy toward projects and loans?
Dhansa Labs reported capital work-in-progress of Rs 29.8714 crore at September 30, 2026, compared with Rs 22.0383 crore at March 31, 2026. The Rs 7.8331 crore increase indicates that spending remained recorded as work in progress rather than being transferred to property, plant and equipment at the reporting date.
The standalone cash-flow statement recorded purchases of fixed assets of Rs 7.8755 crore for the half year ended September 30, 2026, against Rs 1.5150 crore for the half year ended September 30, 2025. The year-on-year increase was Rs 6.3605 crore, while the filing does not provide a project-level reconciliation between fixed-asset purchases and the change in capital work-in-progress.
Dhansa Labs also reported Rs 27.6559 crore under “loan given” in investing cash flows for the half year ended September 30, 2026, compared with Rs 3.6328 crore in the corresponding prior-year period. That cash-flow movement is broadly aligned with the expansion in long-term loans and advances, but the two disclosures use different comparison periods and are not a direct reconciliation.
The cash-flow statement also showed an investment of Rs 9.20 crore in subsidiary companies during the 2026 half year, versus Rs 0.10 crore a year earlier. The balance sheet similarly recorded non-current investments of Rs 9.30 crore, compared with Rs 0.10 crore at March 31, 2026.
How were Dhansa Labs’ advances and projects financed?
Dhansa Labs said it had received Rs 21.6154 crore by September 30, 2026 against 1,08,69,565 convertible equity warrants allotted during the year ended March 31, 2026. The warrants were issued at Rs 46 each, with the disclosed total issue size of Rs 49.9999 crore.
The company said it had utilised the full Rs 21.6154 crore received by September 30, 2026, leaving no unutilised amount. It identified general corporate purposes, advances for plant and machinery, ongoing capital expenditure and land-related advances as the uses, but did not specify amounts allocated to each purpose.
Dhansa Labs reported shareholders’ funds including share capital of Rs 26.9033 crore, reserves and surplus of Rs 67.2457 crore, and Rs 12.6150 crore described as money received against share warrants at September 30, 2026. The supplied balance-sheet presentation does not show comparable March 31 amounts for all shareholders’ funds line items.
Long-term borrowings rose to Rs 23.4367 crore at September 30 from Rs 18.8201 crore at March 31. The cash-flow statement reported net proceeds from long-term borrowings of Rs 4.6076 crore during the half year, compared with Rs 8.1850 crore in the prior-year half year.
Got a follow-up? Ask IRIS
Which liabilities increased on Dhansa Labs’ standalone balance sheet?
Dhansa Labs’ total current liabilities rose by Rs 93.1579 crore to Rs 124.1485 crore at September 30, 2026. Other current liabilities were the largest disclosed component at Rs 79.4772 crore, compared with Rs 2.7329 crore at March 31, and the filing does not provide a component-wise explanation for this category.
Short-term borrowings moved in the opposite direction, falling to Rs 19.5893 crore from Rs 20.745 crore over the six months. Trade payables due to creditors other than micro and small enterprises declined to Rs 2.0077 crore from Rs 5.5943 crore, while dues to micro enterprises increased to Rs 1.2211 crore from Rs 0.6326 crore.
Non-current liabilities increased by Rs 4.6087 crore to Rs 23.8557 crore. Long-term provisions were broadly unchanged at Rs 0.4190 crore, compared with Rs 0.4188 crore at March 31, meaning the movement in non-current liabilities was principally in long-term borrowings.
What did Dhansa Labs report for half-year profit and revenue?
Dhansa Labs reported standalone revenue from operations of Rs 70.5762 crore for the half year ended September 30, 2026, compared with Rs 68.1759 crore for the half year ended September 30, 2025. Net profit after tax was Rs 3.0693 crore, against Rs 2.6217 crore in the corresponding prior-year half year.
The statement reported profit before tax of Rs 2.714 crore for the 2026 half year, compared with Rs 3.0057 crore a year earlier. It also reported tax expense of Rs 1.021 crore, versus Rs 0.3840 crore in the prior-year period, while basic earnings per share were Rs 1.16 compared with Rs 1.05.
Finance cost was Rs 1.5176 crore for the half year ended September 30, 2026, compared with Rs 1.9211 crore a year earlier. Depreciation and amortisation expense was Rs 0.8904 crore, versus Rs 1.1009 crore, and the cash-flow statement separately reported fixed-asset purchases of Rs 7.8755 crore.
Dhansa Labs’ audit committee reviewed the standalone results and its board approved them on November 14, 2026. The independent auditor’s review report stated that nothing had come to its attention to suggest that the standalone unaudited statement failed to make required disclosures, while noting that a review provides moderate assurance and is narrower in scope than an audit.
Conclusion
Dhansa Labs’ September 2026 standalone filing shows balance-sheet growth driven by long-term advances, capital work-in-progress and non-current investments. Long-term loans and advances increased by Rs 28.2841 crore, capital work-in-progress rose by Rs 7.8331 crore, and current liabilities increased by Rs 93.1579 crore, including a sharp rise in other current liabilities.
The next disclosed matter to watch is deployment under the Rs 49.9999 crore convertible-warrant issue. Dhansa Labs had received and utilised Rs 21.6154 crore by September 30, 2026 for stated purposes including plant-and-machinery advances, capital expenditure and land-related advances, but the filing does not give project completion dates, advance counterparties or terms for the Rs 33.9641 crore long-term loans and advances.


